Introduction {#sec1}
============

Molecular machines pass on the information stored in the genetic material to a functional protein, and the sequence of events is known as the central dogma.^[@ref1]^ One of the key players of the information transfer is the enzyme RNA polymerase, catalyzing the first step transcription from DNA to mRNA. The mRNA molecule is then ultimately translated to protein molecules with the help of ribosomes and tRNA.^[@ref2]−[@ref6]^ Transcription is one of the key processes of the central dogma and is intimately tied to the ability of cells to ″make decisions″ about the genes that should be expressed.^[@ref3],[@ref7],[@ref8]^ The bacterial RNA polymerase (RNAP) holoenzyme is a multi-subunit complex (α~2~ββ'ωσ) that performs the essential function of gene transcription.^[@ref9]^ Given the role of RNA polymerase in the central dogma, it was assumed that all the subunits of RNA polymerase would be essential for the survival of the bacteria. However, this is not the case with the smallest subunit ω encoded by the *rpoZ* gene. ω is a small protein with 91 amino acids and has a molecular mass of 10 kDa.

With the increasing availability of the genome sequences of bacteria, archaeal, and eukaryote, it has become clear that the ω-subunit is conserved in all branches of life. In eukaryotes, there exists a structural and functional homologue of ω, *RPB6*, which is found to be associated with RNAP I, II, and III. Further, in archaea, there exists the ω homologue termed *RpoK*.^[@ref10]^ However, over the years, ω was unaccepted as an essential subunit in bacteria mainly because of the following two major observations. In vivo deletion of *rpoZ* is tolerated in bacterial cells unlike the other subunits of RNA polymerase.^[@ref11]^ In addition, reconstitution of *Escherichia coli* RNA polymerase was achieved with purified α, β, and β' subunits, thereby pointing at the redundancy of ω.^[@ref12]^ Eventually, ω was validated as the integral part of RNA polymerase machinery in vivo when the direct association of ω with the β' subunit of RNA polymerase was shown.^[@ref13]^ The subsequent crystal structure of *Thermus aquaticus* RNA polymerase supported this idea.^[@ref14]^ Experiments with RNA polymerase isolated from ω-less strain showed that the multi-subunit enzyme complex copurifies with GroEL, a global chaperone protein, whose removal results in loss of activity of the RNA polymerase enzyme complex.^[@ref15]^ This observation indicates that GroEL substitutes for the function of ω in protection and recruitment of β' during RNA polymerase assembly in a ω-less strain. In support of this argument, it was observed in the RNA polymerase crystal structure that the ω-subunit is latched on to the C-terminal of the β' subunit in such a fashion that a chaperone role of ω in the folding β' subunit can be envisaged.^[@ref14]^ Thus, to examine a system where the functional role of ω can be elucidated without the effect of accessory protein(s), a toxic mutant screen was employed. Mutants were isolated in a way that they would thwart the entry of GroEL in RNA polymerase. This would render the RNA polymerase bound with mutant ω (ω~6~, N60D) inactive during the downstream process.^[@ref16]^ This toxic mutant screen led to the serendipitous discovery of a silent mutant ω~9~, which was lethal. Interestingly, the silent mutant of ω was structured as compared to wild type ω protein, which is mostly disordered.

The genetic code is degenerate, which means that there are multiple codes for the same amino acid. Silent mutations occur when the change of the DNA sequence within a protein-coding portion of a gene does not affect the sequence of amino acids that make up the protein.^[@ref17]−[@ref19]^ This change typically takes place at the third position of the codon also known as the wobble position. A change in one or two nucleotides, however, does not inevitably alter the triplet's meaning; the mutated triplet may still code for the same amino acid. Initially thought to be irrelevant, studies have shown that the occurrence of synonymous codons is nonrandom. In an organism, recurrently used codons are translated rapidly and are termed as frequent codons, while the scarcely used codons are translated at a slower rate and are known as rare codons. Thus, this nonuniform distribution of codons in a gene and abundance of the corresponding isoacceptor tRNA hints at the nonuniform rate of mRNA translation.^[@ref20]−[@ref26]^ Protein expression studies in *Escherichia coli* suggested that translation kinetics and synonymous codon usage can affect protein folding and functions.^[@ref27]−[@ref32]^ There are also reports that have shown that silent polymorphism can lead to the altered structure and function of the protein.^[@ref33]^

Anfinsen's pioneering work showed that a polypeptide chain adopts the native structure, spontaneously, or in other words, the amino acid sequence determines the structure.^[@ref34]^ Protein folding obeys a sequential model with a distinct path and intermediates. However, kinetic and thermodynamic parameters of this path are unamenable to measurements in vivo. Attempts to achieve refolding of denatured protein in vitro were partially successful.^[@ref35]^ In vivo nascent proteins acquire native structures co- and post-translationally, with their half-lives in the range of seconds to minutes, whereas the rate of protein folding varies from seconds to hours in vitro.^[@ref36]−[@ref39]^

After the seminal experiment of Anfinsen on reversible denaturation of ribonuclease, many experiments have suggested cotranslational folding of proteins, small or large in vivo.^[@ref24],[@ref40]−[@ref45]^ Protein biosynthesis without cotranslational folding is likely to be energetically unfavorable.^[@ref43]^ The addition of amino acid on a growing polypeptide chain is dependent on the readability of the frequency of codon, rare or frequent.^[@ref24],[@ref44]−[@ref46]^ Though recent studies suggest that silent mutations can affect the final protein structure, it is unknown if its position within the sequence is relevant. Silent mutation at different positions of the genes will address a few critical questions: (a) will a protein synthesized from silent mutation at different positions necessarily have the same structure as that of wild type protein? (b) does the substitution of a frequent codon to rare codon lead to drastic structure alteration? (c) what is the exact nature of the mutant proteins synthesized from silent mutation in varying positions?

In the present study, we generated several silent mutants by replacing frequent codons to rare codons at different positions of the *rpoZ* gene. This allowed us to determine the delicate balance that exists between the positional effects of codon usage in ω. The important function that was monitored here was the reconstitution of active RNA polymerase with ω variants.

Results {#sec2}
=======

Characterization of the Silent Mutant ω~9~ {#sec2.1}
------------------------------------------

The principal aim of this work was to understand the mechanism behind the structural changes in the ω silent mutant that leads to transcriptionally inactive RNA polymerase. We have shown before that a point mutation results in inactive RNA polymerase with concomitant changes in the helicity of the ω.^[@ref16]^ We have also shown in a recent work that this structural alteration manifests themselves in the strength of binding of β' with the ω-subunit.^[@ref48]^ We would like to emphasize that the silent mutation here for alanine (GCC → GCT) showed no change in the protein sequence yet we observe a lethal phenotype upon induction of protein synthesis ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A). The ω~9~ mutant was obtained as described in Sarkar et al.^[@ref16]^ It must be mentioned here that, at the beginning, we ensured that the overexpression system was not harmful due to the aggregation of proteins and they were purified through overexpression plasmid pET-ω with the T7 promoter. However, we observed no difference in phenotype upon expression of native type and mutant proteins with various promoters. We did not want to alter the chromosomal copy of the *rpoZ* since the polar effect of the mutation plays an important role in *Escherichia coli.*

![Dominant lethal phenotype of ω~9~. (A) Wild type ω and silent mutant ω~9~ in the absence and presence of inducer (IPTG) on LB agar plates. BL21 transformed with plasmid containing ω grows in both the absence and presence of inducer, while BL21 transformed with plasmid containing ω~9~ does not grow upon IPTG induction, showing lethal phenotype. (B) SDS-PAGE of purified proteins, ω and ω~9~, and (C) circular dichroism profile for ω and ω~9~. ω~9~ is more structured than wild type protein ω.](ao9b02103_0003){#fig1}

There are four codons coding for alanine, and the codon usage indexes for all of them are shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. It has been reported before that concentration of the cognate tRNA for rare codon (GCT) is 5 times less concentration than the other tRNA for alanine.^[@ref47],[@ref49]^ To evaluate the significance of this silent mutant, CD spectroscopy was performed with purified proteins ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). We used CD spectroscopy to measure the amount of secondary structure in both wild type ω and silent mutant ω~9~. We observed that ω~9~ is more structured (45% helical) than wild type ω (16% helical) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C). Mass spectroscopic analysis of the purified protein was performed to eliminate the possibility of misincorporation of an amino acid at the mutation site ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf)).

###### Codon Usage Index[a](#t1fn1){ref-type="table-fn"}

  amino acid   codon   codon usage index
  ------------ ------- -------------------
  alanine      GCG     0.36
  alanine      GCA     0.21
  alanine      GCC     0.27
  alanine      GCT     0.16

There are four codons coding for alanine. Out of these, GCG is the most frequent, and GCT is the rarest codon for alanine. The codon usage index tells the frequency with which that codon is used relative to other codons coding for the same amino acid. The codon usage index reported here is for *Escherichia coli*.^[@ref50],[@ref51]^

In Vitro Refolding To Determine the Minimum Energy Structure of a Protein with the Same Amino Acid Sequence {#sec2.2}
-----------------------------------------------------------------------------------------------------------

As mentioned previously, it is established that "the final 3D structure of a protein is defined from its primary amino acid sequence in a given environment".^[@ref34]^ Here, it was observed that, despite possessing the same amino acid sequence, silent mutant ω~9~ acquires a different structure from the wild type ω. The proteins were His-tagged and purified from the soluble cell extract fraction by Ni (II) affinity chromatography. We were interested to find out whether the altered CD profile is in a stable conformation, and thus, urea-dependent denaturation and renaturation experiments were performed. The proteins were completely denatured at time point 0 (urea concn 7 M) ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf)). At the 10th hour, the protein refolded back with removal of urea (urea concn 10 pM), as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. Another ω-variant ω~6~, a lethal mutant (N60D) that shows α-helicity, was used as a control. ω~6~ upon going through the urea denaturation--renaturation cycle reverted to its α-helical conformation. However, ω~9~ reverted to a disordered state like native ω. This observation hints that purified ω~9~, to start with, was not in its stable conformation.

![In vitro refolding. Upon complete denaturation by 7 M urea followed by refolding by dialyzing the proteins against renaturing buffer, ω~9~ folds to a similar structure to wild type ω. ω~6~(N60D) retains its original structure.](ao9b02103_0007){#fig2}

Subsequent analysis by size-exclusion chromatography experiments showed that the wild type, as well as mutant proteins, existed as monomers as shown in [Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf). This rules out the possibility that the change in the structure of the protein is due to the change in the oligomeric status of the protein.

Analyzing Codon Usage in *rpoZ* Gene {#sec2.3}
------------------------------------

We wanted to find out the influence of the rarity of the codons as well as their positions in shaping the secondary structure of the protein. Codon optimality represents a function of the stochastic nature of ribosome decoding of mRNA and the variability of tRNA concentrations. A codon can be defined either as a frequent or a rare codon depending on how efficiently the appropriate cognate tRNA can be selected from the cytoplasmic pool of tRNAs.^[@ref45],[@ref47]^ As follows, codons can be a powerful determinant of translational rates. As shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}, *rpoZ*, which remain a class I gene in *Escherichia coli*, hardly has any nonoptimal or rare codons. The rare codon for alanine, GCU, is present 5 times in the frame and are located close to each other ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). Upon generation of silent mutation at the 82nd position, GCC to GCU, one more time, the rare codon for alanine is introduced proximal to the previously mentioned positions. Our subsequent attempt was to alter the next position, that is, 83rd for valine (GTT → GTA). We altered the third base to introduce the rare codon in place of a frequent codon for valine. However, mutation at this position did not show lethality in the growth curve upon protein induction or CD profile of the protein ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf)).

![Codons used in *rpoZ* gene. *rpoZ* is marked by the presence of fast codons. Rare codons like AGG and AGA for arginine and AUA for isoleucine are not used in the gene.](ao9b02103_0006){#fig3}

![Effect of frequent to rare codon mutation with respect to position: (A) *rpoZ* DNA sequence with highlighted codons for arginine (orange in color) and isoleucine (blue in color). (B) Crystal structure of ω in RNAP complex, with a few mutant positions highlighted in red (ω structure retrieved from 4JKR) and list of mutants with codon positions and amino acids. (C) CD profile for the silent mutants. The rest of the CD profiles are in [Figure S8](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf).](ao9b02103_0005){#fig4}

Positional Effect of Introduction of Rare Codon in *rpoZ* {#sec2.4}
---------------------------------------------------------

It is well recognized that the local rate of translation correlates with the codon usage, which in turn correlates with tRNA population in cells. There is no absolute definition of the rare or frequent codon, but a relative definition can be described. As follows, we decided to investigate the effect of rare codons in *rpoZ* in *Escherichia coli* MG1655. Two rare codons, AGA and AGG, which code for arginine, occur 123 times in the essential genes and 4288 times in the entire genome.^[@ref52]^ On the other hand, isoleucine encoded by AUA is another rare codon that occurs 148 times in essential genes as opposed to 5620 times in the entire genome.^[@ref53]^ Codon usage indexes for all codons encoding arginine and isoleucine are presented in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. Reports showed that these codons are translated at a lower rate.^[@ref54]^ To our benefit, none of these rare codons are present in *rpoZ*, as shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. We generated a series of silent mutants with these rare codons introduced at a different position along the *rpoZ*. Such changes allowed us to investigate the positional effect of a rare codon. Positions of silent mutants on the DNA sequence of *rpoZ* are shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A. They are equally marked in the overall structure of ω ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B), along with the list of mutants. The CD spectra for two mutants are shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C. Mass spectroscopic analysis was performed with purified protein to confirm the protein sequence (not shown).

###### Codon Usage Index for Arginine and Isoleucine[a](#t2fn1){ref-type="table-fn"}

  amino acid   codon   fraction in all genes   fraction in essential genes
  ------------ ------- ----------------------- -----------------------------
  arginine     AGG     0.022                   0.003
  arginine     AGA     0.039                   0.006
  arginine     CGG     0.098                   0.008
  arginine     CGA     0.065                   0.001
  arginine     CGU     0.378                   0.643
  arginine     CGC     0.398                   0.330
  isoleucine   AUA     0.073                   0.006
  isoleucine   AUU     0.507                   0.335
  isoleucine   AUC     0.420                   0.659

AUA (isoleucine) and AGG and AGA (arginine) codons are rarely used in *Escherichia coli.* Their usage reduces in the constitutively expressed genes.^[@ref50],[@ref51]^

It can be noted from [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C that the mutant ω~7~ like ω~9~ is more structured than native ω. There are two sites where a frequent isoleucine codon is mutated to the rare codon, and there are only three codons in between the sites of mutations. However, ω~1~ has a mutation in the N-terminal of the protein and does not demonstrate any structural change ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C). It can be seen from [Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf) that the mutants ω~2~, ω~10~, and ω~5~ like ω~9~ are more structured than native ω. All these mutations occur at the C-terminal unstructured region of the proteins. All other mutants (ω~3~, ω~11~, ω~12~) show little structural element. ω~7~, ω~10~, and ω~9~ have this characteristic feature where the rare codons are present repetitively. They are also present close to each other near the C-terminal and fall in the disordered region predicted by PONDR^[@ref54]^ ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). Mutant-like ω~11~ (arginine silent mutant at the 90th and 91st positions) does not show any change in phenotype or CD spectra of the purified protein. It appears that they fall at the end of the protein synthesis and might not impact the overall sequential folding of the protein.

![Structural transition of ω in *Escherichia coli* CodonPlus strain. (A) Secondary structure prediction for ω by PONDR and the amount of secondary structure present in ω in RNA polymerase crystal structure (PDB ID 4JKR). Free state vs bound state for ω. (B) CD profile of ω~7~ purified from BL21 and CodonPlus.](ao9b02103_0002){#fig5}

Phenotype Rescue in CodonPlus Strain {#sec2.5}
------------------------------------

ω is unstructured in its soluble state, as shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B. Moreover, many algorithms have predicted unstructured segments in ω (12--18%) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). However, when we inspected the crystal structure of *Escherichia coli* RNA polymerase, we observed that ω is more structured in its bound state (63% helical) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). These observations prompted us to think that there is binding-induced folding of ω, and this is important for proper assembly and functioning of RNA polymerase.

There occurs a correlation between codon usage and tRNA population present in the cells, which occupies a crucial role in fine-tuning the local translation kinetics. The tRNA population cognate for the frequent codon is present in abundance in cells, and that for the rare codon is infrequent in the cellular milieu, which in turn affects the translational kinetics.^[@ref46],[@ref47]^ This prompted us to think that the manipulation of the local concentrations of tRNA can influence the translation rate and finally the folding of the protein. Thus, if cells are provided with surplus tRNA copies for the cognate rare codon, folding of the protein can be altered.

The silent mutants, which have acquired structures as opposed to that of wild type ω, were expressed in an *Escherichia coli* CodonPlus strain, which carries an extra gene encoding tRNA cognate for codons AGG, AGA (arginine), and AUA (isoleucine). ω~7~ was expressed in the CodonPlus strain (isoleucine silent mutant at the 49th and 54th positions), and CD spectroscopy was performed on the purified protein. It can be seen from [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B that purified ω~7~ from the CodonPlus strain shows an unstructured CD profile as against that of ω~7~ isolated from BL21. Expectedly, the lethality of the dominant-negative phenotype of *Escherichia coli* cells with ω~7~ (BL21) was rescued in the ω~7~ (CodonPlus) strain in the CFU assay ([Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf)).

Transcriptional Activity of RNA Polymerase Reconstituted in Vitro with Wild Type ω and Its Silent Mutants {#sec2.6}
---------------------------------------------------------------------------------------------------------

ω is a disordered protein, and it has been shown that its flexibility is crucial for the purpose it serves. Studies have shown that the high intramolecular flexibility and plasticity of disordered proteins permit them to bind to their target with high specificity and modulate their function. Structured mutants of ω are rigid as compared to the flexible native protein. We envisaged that the inherent floppiness of the native ω is important for the proper assembly and mobility necessary for the multi-subunit complex RNAP. To verify this, we reconstituted RNA polymerase from individual subunits in vitro (as shown in [Figure S7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf)) and performed a single round transcription assay ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). RNAP reconstituted with ω~6~ was used as a negative control for the experiment. Transcription was carried out in the presence of 0.2 μg/μL heparin essentially to establish the pattern of single round runoff transcription. RNA polymerase isolated from *Escherichia coli* RL916 acting as a positive control. Reconstituted RNA polymerase with native ω showed single round transcription, which was inhibited by rifampicin. RNA polymerase reconstituted with silent mutant ω~7~ was transcriptionally inactive, but single round transcription with ω~7~ (CodonPlus) was positive. We carried out the structural analysis that shows the interaction between ω~7~ and β' in the RNA polymerase complex, as shown in [Figure S5B](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf). It shows that the mutation site and β' residues are present near (5 Å) to each other. A multiround transcription assay was performed with RNA polymerase reconstituted with all the mutants, as depicted in [Figure S7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf), indicating almost 5 times reduced activity for RNA polymerase reconstituted with structured ω mutants.

![Single round transcription assay by in vitro reconstituted RNA polymerase. In all cases, ΔD T7 DNA promoter generating 83 nucleotide long transcript was used. T~7~ A~I~ DNA template (0.4 pmol) and 4 pmol of enzymes were used. The concentration of rifampicin is 10 μM. Lane 1. RNA polymerase from RL916. Lane 2. RNA polymerase from RL916 in the presence of rifampicin. Lane 3. Reconstituted RNA polymerase (α~2~ββ'ωσ). Lane 4. Reconstituted RNA polymerase with ω~7~ purified from BL21 (α~2~ββ'ω~7~σ). Lane 5. Reconstituted RNA polymerase with ω~7~ purified from CodonPlus (α~2~ββ'ω~7~σ). Lane 6. Reconstituted RNA polymerase with ω~1~ purified from BL21 (α~2~ββ'ω~1~σ). Lane 7. Reconstituted RNA polymerase with ω~6~ purified (α~2~ββ'ω~6~σ, negative control). Lane 8. Reconstituted RNA polymerase with ω~9~ (α~2~ββ'ω~9~σ).](ao9b02103_0008){#fig6}

Partial Proteolysis of ω and Its Silent Mutant by Trypsin {#sec2.7}
---------------------------------------------------------

Limited or partial proteolysis is a classic biochemical technique employed to get information regarding the change in protein structure and conformation. Since native ω is an intrinsically disordered protein and its silent mutants are structured, they are expected to indicate the differential rate of digestion by protease. ω has 12 trypsin sites as shown in [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A. We learned from this experiment that, in ω~7~, the C-terminal is getting structured as opposed to that of wild type ω. The differential rate of digestion by trypsin can be noted in [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}B. Mass spectrometric analysis of the assay mixture informed us that there is delayed cutting for intermediate and C-terminal regions of the protein.

![Partial proteolysis of ω by trypsin. (A) Trypsin site on ω protein sequence. (B) Time-based digestion of ω and ω~7~ by trypsin (20% SDS-PAGE). ω was digested at a faster rate than ω~7~.](ao9b02103_0001){#fig7}

ppGpp Interaction with RNAP Reconstituted with ω and Its Silent Mutant {#sec2.8}
----------------------------------------------------------------------

Results on the single round transcription assay presented in a previous section prompted us to assess the binding of ppGpp to RNA polymerase. ppGpp is a nucleotide second messenger, which is known to bind at the ω and β' interface as shown in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}A, which is located at 28 Å distance from the active site of the polymerase complex. ppGpp binding to RNA polymerase possesses a profound effect in regulating *Escherichia coli* transcription.^[@ref55]^ We examined this interaction to understand the influence of ω variants in ppGpp recognition of the enzyme. ppGpp binding to RNA polymerase was titrated by measuring the change in heat capacity of the reaction upon binding. We studied binding affinity of ppGpp to RNA polymerase (α~2~ββ'ω), RNA polymerase reconstituted with ω~9~ (α~2~ββ'ω~9~), and RNA polymerase reconstituted with ω~7~ (α~2~ββ'ω~7~). We observed that there was a reduced binding affinity for ppGpp to RNAP-ω~9~ and RNAP-ω~7~. It indicates that RNA polymerase assembly with mutant ω is defective and that could result in inactive RNA polymerase.

![ppGpp binding to RNAP variants by isothermal calorimetry. (A) Snapshot of crystal structure showing ppGpp interaction with ω and β'. (B) ppGpp interaction with RNA polymerase reconstituted with wild type ω (a), ppGpp interaction with RNA polymerase reconstituted with ω~7~ (b), and ppGpp interaction with RNA polymerase reconstituted with ω~9~ (c). Both RNAP-ω~7~ and RNAP-ω~9~showed reduced ppGpp binding. The PDB ID of the crystal structure of RNA polymerase is 4JKR.](ao9b02103_0004){#fig8}

Discussion {#sec3}
==========

In an open system, Gibb's free energy (Δ*G* = Δ*H* -- *T*Δ*S*) describes the equilibrium. The conversion of unstructured ω to structured ω is accompanied by a negative entropy change, which is compensated by the change in enthalpy. As a result, the overall change in free energy is predominantly negative. By a series of measurements using different techniques, it has been shown that the mutant ω has a stronger binding with the rest of the core enzyme in comparison to that of native ω.^[@ref50]^

Structured ω does bind to α~2~ββ' assembly, which is evident from in vitro reconstitution, but they were defective in transcription. This again hints at the importance of disorderedness of ω. It is well recognized that β' F (bridge)-helix and β' G-loop encompasses the active centers of RNA polymerase and they work in a coordinated fashion to warrant the proper placement of NTPs at the active site and their incorporation into the elongating transcripts. We argue that, due to the binding of the structured ω, the mobility of the flexible segments at the active site is affected, which manifests into the abrogation of initiation of transcription.^[@ref56]^

It appears that the paradigm that describes a direct correlation between structure and function of a protein is not always true with the discovery of the intrinsically disordered proteins. In the last decade, there is a growing amount of evidence for intrinsically disordered proteins, which marks the above assumption.^[@ref57]^ The smallest subunit of RNA polymerase, ω falls in the category of intrinsically disordered protein. Previous reports have shown that the flexibility of ω is critically important for its function and interaction with β'.

Silent mutations were considered inconsequential in terms of protein folding for an extensive period since the encoded protein sequence remains unaltered. However, in eukaryotes, they are appreciated to have an impact on a specialized process like gene splicing and expression levels. However, they are not entirely silent mutants. Although the protein sequence remains the same, the DNA and mRNA sequences are altered due to introduction of the silent mutation. While considering the role of silent mutants, two levels of control need to be considered: (a) rate of translation and (b) mRNA stability. Both may vary as a function of the frequency of codon usage, which would reflect on the protein folding. In the recent past, few observations elegantly demonstrated this point. It would be a bonus for the researchers if differential folding due to single silent mutation exhibits an altered phenotype.

Any study with such a system will direct us to observe the utility of the frequent codon or rare codons, as well as the influence of their positions on the reading frame.

In the present study, the reconstituted RNA polymerase with different ω-subunits shows a lethal dominant-negative phenotype where transcription was inhibited by the same ω-sequence but with an altered folded structure. This unique observation was supported by mainly two experiments, CD studies and single round transcription assay. The former shows a clear folding pattern, whereas the latter demonstrates the functionality. Both experiments are definitive but unfortunately cannot infer various stages of structural alteration or lethality during the path of folding. Our assay mainly focuses on defects in transcription initiation, and thus, we believe that the structure of the active site occupies a critical role.

What represents the nature of this different folded state as they have the same sequence of amino acids? We would like to define them as ″metastable″ state emanated from an altered rate of translation or mRNA stability. That they are metastable and Anfinsen principle ultimately guides their destiny was shown by in vitro urea denaturation--renaturation experiments. As the timescales for protein synthesis and folding are often similar, it is quite evident that the rate of translation can be used to tune the assembly of the growing polypeptide. In this respect, the position of the mutation plays a dominant role. We mentioned before that ω is an intrinsically disordered protein and plasticity of the disordered region during assembly of the functional enzyme is significant. It is interesting to note that all dominant-negative mutants map at the C-terminal region. Thus, it would be worthwhile to investigate which factor-like translation by ribosome or the mRNA structure is playing a significant role here.

Material and Methods {#sec4}
====================

Protein Purification of Wild Type ω and Its Silent Mutants {#sec4.1}
----------------------------------------------------------

DNA sequence coding for ω was cloned into vector pET-28b (Novagen) using NcoI/Hind III restriction sites and was termed as pET-ω. Recombinant plasmids were transformed in *Escherichia coli* BL21 (DE3) grown on LB agar plates containing 50 μg/mL kanamycin. ω and its mutant were purified from the *Escherichia coli* BL21 (DE3) strain transformed unless mentioned otherwise with plasmid pET-ω. The cells were grown at 37 °C to an OD~600~ of 0.6, induced with a final concentration of 1 mM IPTG, and grown further for 3 h. Cells were harvested, and the pellet was dissolved in lysis buffer (50 mM Tris--HCl, pH 7.9; 100 mM NaCl; 1 mM PMSF; 2 mM EDTA; 10 mM benzamidine). Cells were lysed by sonication. The soluble fraction containing the protein was loaded onto a Ni-NTA column pre-equilibrated with the lysis buffer. The column was washed with wash buffer (50 mM Tris--HCl, pH 7.9, 1 mM PMSF, 100 mM NaCl, 10 mM benzamidine, 20 mM imidazole). The protein was eluted out with an elution buffer (50 mM Tris--HCl, pH 7.9, 1 mM PMSF, 100 mM NaCl, 10 mM benzamidine, 0.5 M imidazole). The fractions containing the pure protein were pooled together and dialyzed against storage buffer (20 mM Tris--HCl, pH 7.9; 100 mM NaCl; 0.1 mM DTT; 0.1 mM EDTA, and 50% glycerol). Dialysis was performed at 4 °C for 16 h. The purity of protein was confirmed by analysis on 15% SDS-PAGE, and the concentrations were estimated by the Bradford assay.

Circular Dichroism Spectroscopy {#sec4.2}
-------------------------------

Far UV spectra of ω and its mutants were recorded on a JASCO J-715 CD spectropolarimeter. Buffer used was 50 mM Tris--HCl and 100 mM NaCl, pH 7.9. Mean residue ellipticity was estimated using the formula \[θ\] = (1000 × θ × *m*)/*L* × *C*, where θ is the measured ellipticity in degrees, *m* is the mean residue weight in g/d mol, *C* is the concentration in g/L, and *L* is the path length in cm. The percent α-helicity was calculated using K2D2 software.^[@ref58]^ Protein concentrations used were in the range of 0.2--0.6 mg/mL.

Generation of Silent Mutants of ω at Different Positions {#sec4.3}
--------------------------------------------------------

Mutations were carried out in pET-ω vector bearing wild type ω gene. In order to generate silent mutants of ω, site-directed mutagenesis was performed. Gradient PCR was performed using the primers presented in the primer list in [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf). Following PCR amplification of the vector, amplified products were checked on 1% agarose gel and gel extraction was performed from the band having the desired product. The gel-extracted product was subjected to ligation using T4 DNA ligase provided by NEB followed by *DpnI* digestion and transformation in the DH5α strain of *Escherichia coli. DpnI* digestion was performed to remove the parent plasmid. Cloning results were confirmed by sequencing, and the protein sequence was confirmed by mass analysis.

Refolding Experiment {#sec4.4}
--------------------

Purified ω, ω~9~, and ω~6~ proteins were subjected to denaturation by incubating them with 7 M urea overnight. Urea was dialyzed out in a stepwise manner against the renaturing buffer (50 mM Tris--HCl, 100 mM NaCl), and aliquots were collected every 2 h. Protein refolding was followed by CD spectroscopy.

Reconstitution of RNA Polymerase from Purified Subunits {#sec4.5}
-------------------------------------------------------

Purified subunits Hexahis-α, β, β', and ω and its silent mutants were mixed in a molar ratio of 2:8:4:1 in a mild denaturation buffer (50 mM Tris--HCl, pH 7.9 at 4 °C; 200 mM KCl; 10 mM MgCl~2~; 10% glycerol; 1 mM EDTA, 10 μM ZnCl~2~, and 0.25% *N*-lauryl sarcosine with 10 mM DTT) and kept for an hour at 4 °C. The volume of the reconstitution mixture was kept at 10 mL with a total protein concentration of 1.5 mg/mL. The reconstitution mixture was next dialyzed for 16 h at 4 °C, against 1 L of reconstitution buffer (50 mM Tris--HCl, pH 7.9 at 4 °C; 200 mM KCl; 10 mM MgCl~2~; 20% glycerol; 0.1 mM EDTA, 10 μM ZnCl~2~ with 1 mM DTT). The dialyzed sample was centrifuged at 32000*g* for 30 min, and the clear supernatant was collected. The supernatant was loaded onto the Ni-NTA column matrix, which was pre-equilibrated with the same refolding buffer. The column was washed with 5 column volumes wash buffer (50 mM Tris--HCl, pH 7.9 at 4 °C; 200 mM NaCl; 5% glycerol; 0.1 mM EDTA; 0.1 mM DTT; 20 mM imidazole), and the protein was eluted out with an elution buffer (50 mM Tris--HCl, pH 7.9 at 4 °C; 400 mM NaCl; 5% glycerol; 0.1 mM EDTA; 0.1 mM DTT; 250 mM imidazole). The elusions were checked on an 8--15% gradient SDS-PAGE gel for the presence of the subunits. Eluents from the Ni-NTA column were pooled and concentrated with the help of 100 kDa Centricon. Concentrated RNAP was loaded onto a Heparin-Sepharose column pre-equilibrated with the refolding buffer. The protein was eluted with the elution buffer (10 mM Tris--HCl, pH 7.9 at 4 °C; 800 mM NaCl; 5% glycerol; 0.1 mM EDTA; 0.1 mM DTT). The fractions were checked for the presence of core RNAP on a 10% SDS-PAGE gel, and the purity of the protein was found to be \>99%. Fractions containing reconstituted core RNAP were pooled together and used for the single round transcription assay immediately.

Single Round Transcription Assay {#sec4.6}
--------------------------------

Activity of reconstituted RNAP using wild type ω and its silent mutants was checked by the promoter specific transcription assay. Four picomoles of reconstituted RNAP was preincubated with purified σ70 in a 1:2 molar ratio at 37 ° C for 10 min in the transcription buffer (40 mM Tris--HCl pH 7.9 at 4 ° C, 10 mM MgCl~2~, 75 mM KCl, 0.1 mM EDTA, 0.1 mM DTT, 14 mM β-mercaptoethanol, 0.025 mg/mL nuclease free BSA) to allow formation of the holoenzyme. T~7~A1 promoter DNA was added (0.4 pmol) and incubated for 20 min at 37 °C to allow for specific promoter-RNAP complex formation. Next, the substrate-heparin mixture, containing 0.15 mM ATP, 0.15 mM GTP, 0.15 mM CTP, 0.05 mM UTP, and 2 μCi \[α-P32\]-UTP, was added. The mixture was then incubated for 15 min at 37 °C to allow for the RNA chain elongation reaction. The reaction was terminated with a Stop Solution (5 mM EDTA and 100 μg/mL *Escherichia coli* tRNA). The transcript RNA was precipitated by ethanol, washed, and then separated on a 10% denaturing polyacrylamide gel containing 6 M urea. The gel was put in a fixative solution and exposed to imaging plates, and then the plates were analyzed by a phosphorimager (FLA2000; Fujifilm).

Mass Spectrometry for Protein Analysis {#sec4.7}
--------------------------------------

To verify for the protein of interest, in-gel trypsin digestion was performed alongside ESI analysis. The band corresponding to a molecular marker of 14.4 kDa was cut, destained, and subjected to in-gel tryptic digestion, at pH 7.5 (50 mM ammonium bicarbonate NH~4~HCO~3~), 37 °C overnight. The resulting mixture of tryptic peptides extracted from the gel was passed through a reverse phase column (Zorbax RX C18, 4.6 mm × 250 mm, 5 mm). A gradient elution using H~2~O/ACN/0.1% formic acid was followed at a flow rate of 0.2 mL min^--1^, and the eluting peptides were characterized by conventional MS (LC-ESI-MS) and MS/MS (LC-ESI-MS/MS). An HCT Ultra PTM Discovery mass spectrometer (Bruker Daltonics) has an ESI source and houses a classic ion trap (Paul-type), using which both MS (LC-ESI-MS) and tandem MS (LC-ESI-MS/MS) data were acquired. Both CID and ETD can be carried out within this ion trap in an alternate manner, and thus, the LC-ESI-MS/MS data generated are composed of those resulting from both CID and ETD. While CID is carried out using helium, ETD (ion/ion reaction) is accomplished using fluoranthene radical anions. The fluoranthene radical anions are generated by means of negative chemical ionization utilizing methane as the reagent gas. The ETD (ion/ion) reaction time was set as 100 ms, and the supplemental collisional activation (i.e., smart decomposition) was ON during ETD. The data were processed using Data Analysis Version 4.0 (Bruker Daltonics).

Size-Exclusion Chromatography {#sec4.8}
-----------------------------

Purified protein with a concentration of 1 mg/mL (25 mM Tris--HCl and 100 mM NaCl) was loaded on a Superdex S75 column. Size-exclusion chromatography was performed using GE Healthcare FPLC. The flow rate of the buffer was maintained at 0.3 mL/min. 100 μL volume of protein was injected for the chromatography. Protein elusion was monitored at 315 nm.

Checking for Lethality upon Protein Induction {#sec4.9}
---------------------------------------------

Single colonies were inoculated into LB broth and incubated at 37 °C temperature under shaking conditions. They were recultured in fresh LB tubes with starting 0.1% culture and monitored until OD~600~ reached the value of 0.6. Dilutions were made using LB, and 10 μL was spotted on LB agar plates. For control, plates were not infused with IPTG; however, the test plates had 1 mM IPTG.

Partial Proteolysis by Trypsin {#sec4.10}
------------------------------

1 mg of protein was incubated with trypsin (Promega) for 2, 5, and 10 min in a ratio of trypsin/protein at 1:50. Trypsin was heat-inactivated, and the reaction mixture was loaded onto 20% SDS-PAGE and subjected to mass spectroscopic analysis. All mass spectrometric analysis was performed using a Bruker Ultraflextreme machine.

Isothermal Calorimetry {#sec4.11}
----------------------

An ITC-200 microcalorimeter (GE Healthcare) was used for calorimetry studies. In brief, RNAP reconstituted with and without ω/ω~7~/ω~9~ was taken in the concentration range of 20--50 μM, and ppGpp concentration was varied from 0.1 to 5 mM in all the experiments. Both the ligand and protein were dissolved in a buffer consisting of 20 mM Tris-HCl pH 7.9, 150 mM NaCl and 0.5 mM β-mercaptoethanol. ORIGIN software Version 7.0 (Microcal, Malvern, Worcestershire, U.K.) was used to calculate the binding affinity (*K*~a~). At the time of plotting, the heat of dilution for ppGpp was subtracted and the first data point was removed from the experimental curve as suggested by the analysis software.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b02103](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b02103).Mass spectroscopy, denaturation curves for the proteins, CFU assay to check for protein lethality, and CD spectra ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02103/suppl_file/ao9b02103_si_001.pdf))
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